Susceptibilidad a azoles y anfotericina B de aislados de Candida spp: Experiencia de una red de salud universitaria,entre 2004 y 2010 / Susceptibility to azoles and amphotericin B of isolates of Candida spp: Experience of a university health network, between 2004 and 2010
Rev. chil. infectol
; 29(2): 149-155, abr. 2012. graf, tab
Article
in Es
| LILACS
| ID: lil-627227
Responsible library:
CL1.1
ABSTRACT
Objective:
To describe antifungal susceptibility testing surveillance (December 2004-September 2010) in Candida spp., for amphotericin B, fluconazole and voriconazole, at the Laboratorio de Microbiología, Pontificia Universidad Católica de Chile.Method:
The study was performed utilizing E test and included yeasts from invasive origin and isolates in which antifungal susceptibility testing was asked for by the patient's physician.Results:
The yeasts were mainly recovered from urine samples (n 64), blood cultures (n 51) and secretions (n 24). Two hundred ninety three isolates were studied C. albicans (38%), C. glabrata (30%), C. tropicalis (11%), C. parapsilosis (10%), C. krusei (4%) and others (7%). All Candida species were 100% susceptible to amphotericin B, except C. krusei (1/12). Fluconazole's global susceptibility in C. albicans was 91.8%, but 100% in isolates from blood cultures versus 76% in isolates from urine. C. tropicalis was 93.9% susceptible to fluconazole, C. parapsilosis, 90% and C. glabrata 30.3%. C. krusei had no susceptible isolates to fluconazole. Voriconazole resistance was mainly present in C. glabrata (11.5%).Conclusions:
We recommend the study of antifungal susceptibility in isolates from invasive origin, selected urine strains and C. glabrata. Fluconazole remains effective in C. albicans from blood.RESUMEN
Objetivo:
Describir la susceptibilidad antifúngica in vitro (anfotericina B, fluconazol y voriconazol) de aislados de Candida spp., observada desde diciembre 2004 a septiembre 2010 en el Laboratorio de Microbiología de la Pontificia Universidad Católica de Chile. Material yMétodo:
Se realizó estudio de susceptibilidad mediante E test® a todas las cepas invasoras y a aquellas en que se solicitara dirigidamente antifungigrama (aislados locales o derivados desde otros centros).Resultados:
Se estudiaron 293 aislados, principalmente de muestras de orina (n 64), hemocultivos (n 51) y secreciones (n 24). Las especies correspondieron a C. albicans (38%), C. glabrata (30%), C. tropicalis (11%), C. parapsilosis (10%), C. krusei (4%) y otras (7%). Hubo 100% de susceptibilidad a anfotericina B, excepto en C. krusei (1/12 resistente). La susceptibilidad a fluconazol fue C. albicans 91,8% (100% en aislados de sangre vs 76% en orina); C. tropicalis, 93,9%, C. parapsilosis, 90% y C. glabrata 30,3%. Candida krusei, no tuvo aislados susceptibles a fluconazol. La resistencia a voriconazol se evidenció fundamentalmente en C. glabrata (11,5%).Conclusiones:
Recomendamos realizar estudio de susceptibilidad en aislados de muestras invasoras, casos seleccionados de cepas de orina y ante sospecha de C. glabrata. Fluconazol mantiene efectividad en C. albicans proveniente de sangre.Key words
Full text:
1
Index:
LILACS
Main subject:
Pyrimidines
/
Triazoles
/
Candida
/
Fluconazole
/
Amphotericin B
/
Antifungal Agents
Type of study:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Humans
Country/Region as subject:
America do sul
/
Chile
Language:
Es
Journal:
Rev. chil. infectol
Journal subject:
DOENCAS TRANSMISSIVEIS
Year:
2012
Type:
Article